罗格列酮对肝星状细胞MMP-2、TIMP-1 mRNA表达的影响  

Effects of Rosiglitazone on expressions of MMP-2 and TIMP-1 mRNA in hepatic stellate cells

作　　者：李森林[1] 赵景润[1] 任晓燕[1] 马青竹[1] 谢佳平[1] 李振方[1] 郎翠翠[1] 

机构地区：[1]聊城市人民医院消化内科,山东聊城252000

出　　处：《山东大学学报（医学版）》2009年第11期74-75,79,共3页Journal of Shandong University:Health Sciences

摘　　要：目的探讨罗格列酮对体外培养肝星状细胞MMP-2及TIMP-1基因表达的影响。方法采用HSC-T6肝星状细胞系,经不同浓度的罗格列酮干预,采用RT-PCRA法检测各组MMP-2及TIMP-1基因的表达情况。结果在10、20μmol/L罗格列酮组,TIMP-1的表达较空白对照组明显降低(P<0.05),而MMP-2的表达与空白对照组相比差异无统计学意义。结论罗格列酮的抗肝纤维化作用与抑制HSC表达TIMP-1有关。Objective To investigate the effects of Rosiglitazone on expressions of MMP-2 and TIMP-1 mRNA in hepatic stellate cells（HSCs） in vitro.Methods The HSC line,HSC-T6 was incubated with different concentrations of Rosiglitazone.The MMP-2 and TIMP-1 mRNA levels were measured by reverse-transcription polymerase chain reaction（RT-PCR）.Results Expression of TIMP-1 mRNA in the Rosiglitazone-treatment groups was significantly lower than that in the control group（P〈0.05）,and there was no difference in the MMP-2 mRNA levels between the Rosiglitazone-treatment groups and the control group.Conclusion The anti-fibrosis mechanism of Rosiglitazone is partly due to its down-regulation on TIMP-1 but not on MMP-2 expression of hepatic stellate cells.

关 键 词：罗格列酮 肝星状细胞 基质金属蛋白酶-2 金属蛋白酶组织抑制因子-1 

分 类 号：R575[医药卫生—消化系统]